Published in Mol Ther on January 18, 2011
Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med (2011) 11.01
Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA. Science (2014) 2.93
Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med (2014) 2.92
Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood (2013) 1.98
Systemic errors in quantitative polymerase chain reaction titration of self-complementary adeno-associated viral vectors and improved alternative methods. Hum Gene Ther Methods (2012) 1.79
Analysis of transduction efficiency, tropism and axonal transport of AAV serotypes 1, 2, 5, 6, 8 and 9 in the mouse brain. PLoS One (2013) 1.70
Overcoming preexisting humoral immunity to AAV using capsid decoys. Sci Transl Med (2013) 1.56
Superior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid. Mol Ther (2016) 1.54
Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy. J Clin Invest (2013) 1.44
Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood (2013) 1.36
Induction of hepatocellular carcinoma by in vivo gene targeting. Proc Natl Acad Sci U S A (2012) 1.31
Innate Immune Responses to AAV Vectors. Front Microbiol (2011) 1.24
Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia B. Mol Ther (2012) 1.13
Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol (2016) 1.11
Synergistic effects of central nervous system-directed gene therapy and bone marrow transplantation in the murine model of infantile neuronal ceroid lipofuscinosis. Ann Neurol (2012) 1.05
Manufacturing of recombinant adeno-associated viral vectors for clinical trials. Mol Ther Methods Clin Dev (2016) 1.05
Animal models of hemophilia. Prog Mol Biol Transl Sci (2012) 1.04
Limitations of encapsidation of recombinant self-complementary adeno-associated viral genomes in different serotype capsids and their quantitation. Hum Gene Ther Methods (2012) 1.04
Cardiac gene transfer of short hairpin RNA directed against phospholamban effectively knocks down gene expression but causes cellular toxicity in canines. Hum Gene Ther (2011) 1.01
Stable human FIX expression after 0.9G intrauterine gene transfer of self-complementary adeno-associated viral vector 5 and 8 in macaques. Mol Ther (2011) 1.00
Integration frequency and intermolecular recombination of rAAV vectors in non-human primate skeletal muscle and liver. Mol Ther (2012) 0.98
Balloon catheter delivery of helper-dependent adenoviral vector results in sustained, therapeutic hFIX expression in rhesus macaques. Mol Ther (2012) 0.96
Minimizing the inhibitory effect of neutralizing antibody for efficient gene expression in the liver with adeno-associated virus 8 vectors. Mol Ther (2012) 0.96
Gene therapy for hemophilia. Front Biosci (Landmark Ed) (2015) 0.94
Displaying high-affinity ligands on adeno-associated viral vectors enables tumor cell-specific and safe gene transfer. Mol Ther (2012) 0.92
CD8+ T cell recognition of epitopes within the capsid of adeno-associated virus 8-based gene transfer vectors depends on vectors' genome. Mol Ther (2013) 0.91
Role of antigen-specific regulatory CD4+CD25+ T cells in tolerance induction after neonatal IP administration of AAV-hF.IX. Gene Ther (2013) 0.91
Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions. Front Immunol (2014) 0.91
Liver-Directed Adeno-Associated Viral Gene Therapy for Hemophilia. J Genet Syndr Gene Ther (2012) 0.90
Development of gene therapy for blood disorders: an update. Blood (2013) 0.90
The threefold protrusions of adeno-associated virus type 8 are involved in cell surface targeting as well as postattachment processing. J Virol (2012) 0.90
AAV-mediated gene transfer in the perinatal period results in expression of FVII at levels that protect against fatal spontaneous hemorrhage. Blood (2011) 0.89
Comparison of adeno-associated virus serotypes and delivery methods for cardiac gene transfer. Hum Gene Ther Methods (2012) 0.89
Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B. J Transl Med (2014) 0.89
Preclinical dose-finding study with a liver-tropic, recombinant AAV-2/8 vector in the mouse model of galactosialidosis. Mol Ther (2011) 0.88
Advancements in adeno-associated viral gene therapy approaches: exploring a new horizon. F1000 Med Rep (2011) 0.88
Self-complementary adeno-associated viral vectors for gene therapy of hemophilia B: progress and challenges. Expert Rev Hematol (2011) 0.87
AAV vector biology in primates: finding the missing link? Mol Ther (2011) 0.86
Gene therapy for haemophilia: prospects and challenges to prevent or reverse inhibitor formation. Br J Haematol (2011) 0.86
Disease correction by combined neonatal intracranial AAV and systemic lentiviral gene therapy in Sanfilippo Syndrome type B mice. Gene Ther (2013) 0.86
Extracting structural and functional features of widely distributed biological circuits with single cell resolution via tissue clearing and delivery vectors. Curr Opin Biotechnol (2016) 0.86
Clinical development of gene therapy: results and lessons from recent successes. Mol Ther Methods Clin Dev (2016) 0.85
Perinatal gene transfer to the liver. Curr Pharm Des (2011) 0.84
Gene therapy for immune tolerance induction in hemophilia with inhibitors. J Thromb Haemost (2016) 0.84
Preferential targeting of disseminated liver tumors using a recombinant adeno-associated viral vector. Hum Gene Ther (2015) 0.83
Platelet gene therapy by lentiviral gene delivery to hematopoietic stem cells restores hemostasis and induces humoral immune tolerance in FIX(null) mice. Mol Ther (2013) 0.83
Neutralizing Antibodies Against Adeno-Associated Viral Capsids in Patients with mut Methylmalonic Acidemia. Hum Gene Ther (2016) 0.82
Gene therapy for mucopolysaccharidosis type VI is effective in cats without pre-existing immunity to AAV8. Hum Gene Ther (2013) 0.82
Prevalence of anti-adeno-associated virus serotype 8 neutralizing antibodies and arylsulfatase B cross-reactive immunologic material in mucopolysaccharidosis VI patient candidates for a gene therapy trial. Hum Gene Ther (2015) 0.81
An siRNA Screen Identifies the U2 snRNP Spliceosome as a Host Restriction Factor for Recombinant Adeno-associated Viruses. PLoS Pathog (2015) 0.81
Preclinical Potency and Biodistribution Studies of an AAV 5 Vector Expressing Human Interferon-β (ART-I02) for Local Treatment of Patients with Rheumatoid Arthritis. PLoS One (2015) 0.81
Enhanced T cell function in a mouse model of human glycosylation. J Immunol (2013) 0.79
Intravenous AAV8 Encoding Urocortin-2 Increases Function of the Failing Heart in Mice. Hum Gene Ther (2015) 0.79
Successful Phenotype Improvement following Gene Therapy for Severe Hemophilia A in Privately Owned Dogs. PLoS One (2016) 0.79
A barrel of monkeys: scAAV8 gene therapy for hemophilia in nonhuman primates. Mol Ther (2011) 0.79
Proteasome inhibition is partially effective in attenuating pre-existing immunity against recombinant adeno-associated viral vectors. PLoS One (2012) 0.79
Coagulation Factor IX for Hemophilia B Therapy. Acta Naturae (2012) 0.79
Similar therapeutic efficacy between a single administration of gene therapy and multiple administrations of recombinant enzyme in a mouse model of lysosomal storage disease. Hum Gene Ther (2014) 0.78
Our journey to successful gene therapy for hemophilia B. Hum Gene Ther (2014) 0.78
Platelet and endothelial expression of clotting factors for the treatment of hemophilia. Thromb Res (2012) 0.78
Developments in the treatment of hemophilia B: focus on emerging gene therapy. Appl Clin Genet (2013) 0.77
Inhibitors - cellular aspects and novel approaches for tolerance. Haemophilia (2014) 0.77
Progress towards gene therapy for haemophilia B. Int J Hematol (2014) 0.77
Effects of FVIII immunity on hepatocyte and hematopoietic stem cell-directed gene therapy of murine hemophilia A. Mol Ther Methods Clin Dev (2016) 0.76
Portal vein delivery of viral vectors for gene therapy for hemophilia. Methods Mol Biol (2014) 0.76
High cerebrospinal fluid levels of interleukin-10 attained by AAV in dogs. Gene Ther (2014) 0.76
An Immune-Competent Murine Model to Study Elimination of AAV-Transduced Hepatocytes by Capsid-Specific CD8(+) T Cells. Mol Ther Methods Clin Dev (2017) 0.75
Gene Therapy for Metabolic Diseases. Transl Sci Rare Dis (2016) 0.75
The interplay of post-translational modification and gene therapy. Drug Des Devel Ther (2016) 0.75
Low-dose Gene Therapy Reduces the Frequency of Enzyme Replacement Therapy in a Mouse Model of Lysosomal Storage Disease. Mol Ther (2016) 0.75
Effective Depletion of Pre-existing Anti-AAV Antibodies Requires Broad Immune Targeting. Mol Ther Methods Clin Dev (2017) 0.75
Hemophilia B gene therapy in humans shows promise. Circ Cardiovasc Genet (2012) 0.75
Transient suppression of hepatocellular replication in the mouse liver following transduction with recombinant adeno-associated virus. Gene Ther (2015) 0.75
Pharmacodynamics of anti-HIV gene therapy using viral vectors and targeted endonucleases. J Antimicrob Chemother (2016) 0.75
Endogenous migration modulators as parent compounds for the development of novel cardiovascular and anti-inflammatory drugs. Br J Pharmacol (2012) 0.75
Induction of Immune Tolerance to Foreign Protein via Adeno-Associated Viral Vector Gene Transfer in Mid-Gestation Fetal Sheep. PLoS One (2017) 0.75
Ultramicroscopy as a novel tool to unravel the tropism of AAV gene therapy vectors in the brain. Sci Rep (2016) 0.75
In Utero Transfer of Adeno-Associated Viral Vectors Produces Long-Term Factor IX Levels in a Cynomolgus Macaque Model. Mol Ther (2017) 0.75
Successful Repeated Hepatic Gene Delivery in Mice and Non-human Primates Achieved by Sequential Administration of AAV5(ch) and AAV1. Mol Ther (2017) 0.75
Non-clinical Safety and Efficacy of an AAV2/8 Vector Administered Intravenously for Treatment of Mucopolysaccharidosis Type VI. Mol Ther Methods Clin Dev (2017) 0.75
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med (2006) 13.51
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A (2002) 11.11
Expansions of transgene repeats cause heterochromatin formation and gene silencing in Drosophila. Cell (1994) 4.83
Repeat-induced gene silencing in mammals. Nat Genet (1998) 4.74
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood (2002) 4.60
Inactivation of gene expression in plants as a consequence of specific sequence duplication. Proc Natl Acad Sci U S A (1994) 3.91
AAV vector integration sites in mouse hepatocellular carcinoma. Science (2007) 3.73
Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J Virol (2004) 3.65
Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J Virol (2001) 3.38
Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. J Virol (2005) 3.28
Chromatin silencing and the maintenance of a functional germline in Caenorhabditis elegans. Development (1998) 3.14
Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid. Nat Med (2006) 2.78
A factor IX-deficient mouse model for hemophilia B gene therapy. Proc Natl Acad Sci U S A (1997) 2.22
Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver. Mol Ther (2006) 2.15
Large-scale molecular characterization of adeno-associated virus vector integration in mouse liver. J Virol (2005) 2.09
The pleiotropic effects of natural AAV infections on liver-directed gene transfer in macaques. Mol Ther (2009) 2.08
Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood (2007) 2.05
Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model. J Virol (1999) 1.95
Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA. Blood (2001) 1.74
Characterization of adeno-associated virus genomes isolated from human tissues. J Virol (2005) 1.72
Canine hemophilia B resulting from a point mutation with unusual consequences. Proc Natl Acad Sci U S A (1989) 1.68
Inhibitor development in haemophilia B: an orphan disease in need of attention. Br J Haematol (2007) 1.63
Prospects for gene therapy of haemophilia. Haemophilia (2004) 1.59
Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B. Blood (2010) 1.50
The morphology, immunohistochemistry, and incidence of hematopoietic neoplasms in mice and rats. Toxicol Pathol (1993) 1.43
Lifespan, age changes and tumour incidence in an ageing C57BL mouse colony. Lab Anim (1976) 1.38
Permanent phenotypic correction of hemophilia B in immunocompetent mice by prenatal gene therapy. Blood (2004) 1.30
Enhancing transduction of the liver by adeno-associated viral vectors. Gene Ther (2008) 1.24
No evidence for tumorigenesis of AAV vectors in a large-scale study in mice. Mol Ther (2005) 1.20
In utero gene transfer of human factor IX to fetal mice can induce postnatal tolerance of the exogenous clotting factor. Blood (2002) 1.16
Manufacturing and characterizing AAV-based vectors for use in clinical studies. Gene Ther (2008) 1.15
Evidence for repeat-induced gene silencing in cultured Mammalian cells: inactivation of tandem repeats of transfected genes. Exp Cell Res (2002) 1.13
Infectious titer assay for adeno-associated virus vectors with sensitivity sufficient to detect single infectious events. Hum Gene Ther (2004) 1.10
Diversity of homology-dependent gene silencing strategies in fungi. Curr Opin Microbiol (2000) 1.03
Targeted inactivation of the coagulation factor IX gene causes hemophilia B in mice. Blood (1998) 1.02
Current status and prospects for gene therapy. Vox Sang (2004) 0.88
Neonatal intravenous injection of a gammaretroviral vector has a low incidence of tumor induction in mice. Hum Gene Ther (2008) 0.86
Translocations of 17q21 approximately qter in neuroblastoma cell lines infrequently include the topoisomerase IIalpha gene. Cancer Genet Cytogenet (2006) 0.83
Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med (2008) 17.21
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med (2006) 13.51
Projection of an immunological self shadow within the thymus by the aire protein. Science (2002) 12.15
Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med (2011) 11.01
Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci U S A (2003) 9.14
Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell (2006) 8.48
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet (2009) 6.71
Telomere dysfunction induces metabolic and mitochondrial compromise. Nature (2011) 6.36
The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res (2005) 5.93
CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med (2007) 5.24
In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature (2011) 4.81
Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet (2011) 4.67
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood (2002) 4.60
Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell (2005) 4.14
Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther (2009) 3.93
Agriculture: Feeding the future. Nature (2013) 3.75
Herpes simplex virus 1 interaction with Toll-like receptor 2 contributes to lethal encephalitis. Proc Natl Acad Sci U S A (2004) 3.74
AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood (2009) 3.65
Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest (2003) 3.52
Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLoS Biol (2004) 3.48
High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell (2004) 3.46
Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood (2002) 3.45
Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer. Mol Ther (2008) 3.28
Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes. Mol Ther (2007) 3.26
Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature (2010) 3.03
Doubling genome size without polyploidization: dynamics of retrotransposition-driven genomic expansions in Oryza australiensis, a wild relative of rice. Genome Res (2006) 3.02
Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res (2007) 2.97
Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med (2014) 2.92
AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med (2012) 2.87
Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKClambda/zeta. Cell Metab (2006) 2.82
Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood (2006) 2.67
Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer (2007) 2.62
New ISSCR guidelines underscore major principles for responsible translational stem cell research. Cell Stem Cell (2008) 2.61
Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood (2009) 2.55
Molecular evidence for a single evolutionary origin of domesticated rice. Proc Natl Acad Sci U S A (2011) 2.53
Assessing the potential for AAV vector genotoxicity in a murine model. Blood (2010) 2.48
Exogenous control of mammalian gene expression through modulation of RNA self-cleavage. Nature (2004) 2.48
Wisconsin Medicaid enrollees' recurrent use of emergency departments and physicians' offices for treatment of nontraumatic dental conditions. J Am Dent Assoc (2011) 2.46
Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology (2011) 2.35
Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. Mol Ther (2006) 2.33
Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates. Proc Natl Acad Sci U S A (2007) 2.30
Good manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trial. Hum Gene Ther (2011) 2.29
Loss of Pin1 function in the mouse causes phenotypes resembling cyclin D1-null phenotypes. Proc Natl Acad Sci U S A (2002) 2.28
Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration. Nature (2003) 2.28
Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells. Blood (2005) 2.27
The Oryza bacterial artificial chromosome library resource: construction and analysis of 12 deep-coverage large-insert BAC libraries that represent the 10 genome types of the genus Oryza. Genome Res (2005) 2.23
TCR-inducible PLZF transcription factor required for innate phenotype of a subset of gammadelta T cells with restricted TCR diversity. Proc Natl Acad Sci U S A (2009) 2.13